To r

egis

ter

visi

t go

top

er.c

om/g

o/N

YL1

8TR

I

This

activ

ity

has b

een

appr

oved

for

AM

A P

RA

Cat

egor

y 1

Cre

dit™

SATU

RDAY

, NO

VEM

BER

10, 2

018

New

Yor

k M

arrio

tt M

arqu

is 15

35 B

road

way

| N

ew Y

ork,

NY

1003

6

Prog

ram

Cha

irs

Mar

k G

. Kris

, MD

A

tten

din

g, T

hora

cic

Onc

olo

gy

Serv

ice

Will

iam

and

Jo

y R

uane

Cha

ir in

Tho

raci

c O

nco

log

y M

emo

rial

Slo

an K

ette

ring

Can

cer C

ente

r N

ew Y

ork

, NY

Rom

an P

erez

-Sol

er, M

D

Cha

irm

an, D

epar

tmen

t of O

nco

log

y M

ont

efio

re M

edic

al C

ente

r Pr

ofe

sso

r of M

edic

ine

and

Mo

lecu

lar P

harm

aco

log

y D

eput

y C

ance

r Cen

ter D

irect

or

Alb

ert E

inst

ein

Co

lleg

e o

f Med

icin

e B

ronx

, NY

SATU

RDAY

, NO

VEM

BER

10, 2

018

New

Yor

k M

arrio

tt M

arqu

is 15

35 B

road

way

| N

ew Y

ork,

NY

1003

6

Vis

it u

s at

goto

per

.com

/go/

NY

L18T

RI

REGISTRATION FEES ADVANCED ON-SITEPhysicians $159 $199Fellows* $109 $149Nurses, PAs, other $109 $149Industry** $359 $399

*FELLOWS registration must be accompanied by a letter from your director/chair stating current fellowship for discount. **INDUSTRY is defined by PER® as any person employed by a for-profit organization, including biotech, financial, and pharmaceutical.

A cancellation fee of 25% will be assessed on refunds requested through and including October 14, 2018, and a 50% fee applies to refunds requested from October 15, 2018 through November 4, 2018. No refunds will be made after November 4, 2018. There is no charge for substitution. Substitutions can only be applied to the same conference and only two substitutions will be honored.

Phys

icia

ns’ E

duca

tion

Reso

urce

®, L

LC2

Cla

rke

Driv

e, S

uite

110

Cra

nbur

y, N

J 085

12

• In

tegr

ate

rece

nt d

ata

into

you

r pra

ctic

e•

Inte

ract

with

the

expe

rt fa

culty

and

col

leag

ues

Heather M. Hylton, MS, PA-C (Planning Committee)Director of Physician Assistant Services Department of Medicine Memorial Sloan Kettering Cancer CenterNew York, NY

Michael F. Berger, PhDAssociate Director, Marie-Josée and Henry R. Kravis Center for

Molecular OncologyMemorial Sloan Kettering Cancer CenterNew York, NY

D. Ross Camidge, MD, PhDProfessor with Tenure, Division of Medical Oncology - Joyce Zeff

Chair in Lung Cancer ResearchUniversity of Colorado Denver School of MedicineDenver, CO

Robert J. Cerfolio, MD, MBAProfessor, Department of Cardiothoracic SurgeryDirector, Clinical Thoracic SurgeryDirector, NYU Langone Lung Cancer CenterSenior Consultant, Robotic Surgery CenterNYU Langone HealthNew York, NY

Jamie E. Chaft, MDAssistant AttendingThoracic Oncology serviceMemorial Sloan Kettering Cancer CenterNew York, NY

Mohit Chawla, MD, FCCPChief, Pulmonary ServiceDirector, Section of Interventional PulmonologyProgram Director, Interventional Pulmonology FellowshipMemorial Sloan Kettering Cancer CenterNew York, NY

Walter J. Curran, Jr., MD Executive Director Winship Cancer Institute of Emory UniversityAtlanta, GA

Balazs Halmos, MD, MSProfessor of Clinical MedicineDirector, Thoracic/Head&Neck Medical Oncology Director, Clinical Cancer GenomicsAlbert Einstein College of Medicine/Montefiore Medical CenterBronx, NY

Nasser Hanna, MDProfessor of MedicineTom and Julie Wood Family Foundation Professor of Lung Cancer

Clinical ResearchIndiana University Melvin and Bren Simon Cancer CenterIndianapolis, IN

Roy S. Herbst, MD, PhD Ensign Professor of Medicine (Medical Oncology) Professor of Pharmacology Chief of Medical Oncology Associate Director for Translational ResearchYale Cancer Center, Smilow Cancer HospitalNew Haven, CT

David R. Jones, MDChief, Thoracic Service, Department of SurgeryCo-Director, Druckenmiller Center for Lung Cancer ResearchFiona and Stanley Druckenmiller Chair in Lung CancerMemorial Sloan Kettering Cancer CenterNew York, NY

Nitin Ohri, MD, MSRadiation OncologyMontefiore Medical Center Associate Professor, Department of Radiation OncologyAlbert Einstein College Of MedicineBronx, NY

Ronald J. Scheff, MDAssistant Professor of Clinical MedicineDirector, Fellowship Training ProgramWeill Cornell Medicine Weill Cornell Cancer CenterNew York, NY

Lawrence H. Schwartz, MDChair, Department of RadiologyProfessor of RadiologyColumbia Vagelos College of Physicians and Surgeons New York-Presbyterian Hospital/ ColumbiaNew York, NY

Steven E. Vogl, MDMedical Oncologist Montefiore Medical CenterNew York, NY

Maureen F. Zakowski, MDThe Mount Sinai HospitalNew York, NY

*Faculty Accurate at Time of Printing

FACULTY

TWO WAYS TO REGISTER

Online CallVisit us online at

gotoper.com /go/NYL18TRI

For any other question email us at: info@gotoper.com

1-609-378-3701

or

Integrate Recent Data into Your Prac tice!

This meeting allows me to stay up-to-date with the newest studies and practices in lung cancer.

NETWORKING BREAKFAST SESSION FOR NURSE PRACTITIONERS AND PHYSICIANS ASSISTANTS 6:00 am Registration and Breakfast6:30 am NP/PA Session7:30 am Adjourn

GENERAL SESSION6:30 am Registration and Breakfast7:30 am Welcome, Introductions, and Pre-Session SurveySESSION I: MAKING THE DIAGNOSIS OF LUNG CANCERS - 2018 PERSPECTIVES7:40 am Role of the Thoracic Surgeon in Lung Cancer Diagnosis7:55 am Key Considerations from the Interventional Radiologist in Diagnostic

Approaches8:10 am The Pulmonologist’s Role in Lung Cancer Diagnosis8:25 am Essentials of Pathology for the Diagnosis of Lung Cancers8:40 am Next-Generation Sequencing: One-Stop Shopping8:55 am Question-and-Answer SessionSESSION II: PERIOPERATIVE THERAPY9:05 am What is the Best Neoadjuvant Therapy?9:20 am Choosing the Optimal Adjuvant Systemic Therapy9:35 am The Role of Adjuvant Radiation in Resectable Disease9:50 am Question-and-Answer Session10:00 am BREAKSESSION III: UNRESECTABLE AND INOPERABLE LUNG CANCERS10:25 am Primary Radiation Therapy: Optimal Dose and Schedule10:40 am Should All Patients With Stage III NSCLC Receive Consolidation

Immunotherapy?10:55 am Post-Session Survey11:00 am Question-and-Answer SessionPUTTING THE DATA INTO PRACTICE: CHALLENGING CASES IN LUNG CANCERS11:15 am Challenging Cases

12:00 pm LUNCH1:15 pm Pre-Session SurveySESSION IV: METASTATIC LUNG CANCERS1:20 pm Choosing the Best Initial Therapy in the Absence of an Oncogenic Driver1:35 pm What is the Best Initial Therapy for Oncogene-Driven NSCLC?1:50 pm When to Change Systemic Therapy?2:05 pm How to Select Subsequent Therapy (No Oncogenic Driver)2:20 pm How to Select Subsequent Therapy (Oncogene-Driven NSCLC)2:35 pm Question-and-Answer Session2:50 pm Post-Session Survey2:55 pm BREAKPUTTING THE DATA INTO PRACTICE: CHALLENGING CASES IN LUNG CANCERS3:20 pm Challenging CasesSESSION V: THE NEXT BIG THING IN LUNG CANCER4:05 pm Thoracic Surgery 4:20 pm Radiation Oncology 4:35 pm Pulmonary Medicine 4:50 pm Emerging Oncogenic Drivers5:05 pm Imaging 5:20 pm Systemic Therapies 5:35 pm Question-and-Answer Session5:45 pm Closing Remarks and Adjourn

*Agenda accurate at time of printing

Moderator: Heather M. Hylton, MS, PA-C

SATURDAY, NOVEMBER 10, 2018New York Marriott Marquis 1535 Broadway | New York, NY 10036

OverviewAt the 13th Annual New York Lung Cancers Symposium, you will experience a comprehensive overview of lung cancer diagnosis and multidisciplinary treatment. For 2018, we have redesigned the meeting to help you increase your understanding of lung cancer therapy, starting with the role of surgery, radiology, pulmonology, and pathology in ensuring the most accurate diagnosis of lung cancers. You will also hear national experts discuss optimal approaches for early-stage and locally advanced disease, as well as the latest on immunotherapy and targeted agents in metastatic lung cancers. Finally, you will get a preview of upcoming advances in local and systemic therapies. For nurse practitioners and physicians assistants, a special breakfast session will provide opportunities for learning and networking.

Benefits in Attending This Year’s New York Lung Cancers Symposium:• Multidisciplinary approaches for patient diagnosis

• Perioperative strategies for your patients with resectable disease

• Immunotherapy and local modalities for stage III lung cancers

• Targeting immune checkpoints and oncogenic drivers in your patients with metastatic lung cancers

• Application of clinical data in challenging case scenarios

Physicians’ Education Resource®, LLC is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

This activity has been approved for AMA PRA Category 1 Credit™

Physicians’ Education Resource®, LLC is approved by the California Board of Registered Nursing, Provider #16669.

This activity is supported by educational grants from AstraZeneca, Bristol-Myers Squibb, Lilly, and Pfizer.

For further information concerning Lilly grant funding visit www.lillygrantoffice.com.

For more information and to register visit gotoper.com/go/N YL18TRI

Agenda